BIOGRAPHICAL SKETCH

NAME: Zhong Liu

POSITION TITLE: Vice Director of General Surgery of Shenzhen University General Hospital

EDUCATION/TRAINING

A. Personal statement

Zhong Liu is MD, postdoctoral fellow of Tokyo National Center for Child Health and Development, and Master Supervisor of Shenzhen University Medical College. Dr. Liu is the Vice Director of General Surgery of Shenzhen University General Hospital, Chief Physician and Professor. Dr. Liu is mainly engaged in the clinical diagnosis and treatment of gastrointestinal and anal diseases and inguinal hernia, especially in the laparoscopic treatment of gastric and colorectal cancer, as well as the minimally invasive treatment of perianal benign diseases and inguinal hernia. Dr. Liu serves as a member of the Anorectal Branch of Chinese Medical Association, a member of the Surgery Branch of Guangdong Medical Association, and a member of the Surgical Professional Committee of Shenzhen Medical Association. Dr. Liu^’s research direction is in immunotherapy of gastrointestinal tumors and immune tolerance of organ transplantation. He has chaired >10 research projects including general projects of the National Natural Science Foundation. He has published >50 papers, among which >10 are in SCI-Indexed articles as first or corresponding author.

B. Positions and honors

Positions

2018- present: Chief Physician, Professor, Vice Director of General Surgery, Shenzhen University General Hospital, Shenzhen, China.

2001- 2017: Chief Physician, Professor, The First Affiliated Hospital of Dalian Medical University, Dalian, China.

Honors

C. Representative publications (selected publications in recent five years   5-10篇)

1.Cui Deli, Tang Changjun, Liu Zhong. An Alternative Technique of Arterial Anastomosis in Mouse Heart Transplantation. Clin Transplant, 2018, 32(6):e13264. (corresponding author)

2.Wang Lei, Liang Wentao, Peng Na, Hu Xiang, Xu Yingxin, Liu Zhong. The synergistic antitumor effect of arsenic trioxide combined with cytotoxic T cells in pulmonary metastasis model of colon cancer. Oncotarget, 2017, 8(65): 109609-109618. (corresponding author)

3.Wang Lei, Hu Xiang, Xu Yinxin, Liu Zhong. Arsenic trioxide inhibits lung metastasis of mouse colon cancer via reducing the infiltration of regulatory T cells. Tumor Biology, 2016, 37(11):15165-15173. (corresponding author)

4.Ge Zheng, Liu Zhong, Hu Xiang. Anatomic distribution, clinical features, and survival data of 87 cases primary gastrointestinal lymphoma. World J Surg Oncol, 2016, 14:85. (corresponding author)

5.Wen Shijun, Liu Zhong, Hu Xiang. Clinical Features and Prognostic Analysis of AFP Positive Gastric Cancer. Zhonghua Wei Chang Wai Ke Za Zhi, 2016,19(1):67‐70.(corresponding author)

D. Research support

Ongoing projects (RMB)

1. Study on immune tolerance of mice heart transplantation induced by fecal microbiota transplantation combined with Chailing decoction based on gut microbiota-regulatory T cell pathway, The National Natural Science Foundation of China (81973664), 01/01/2020 to 12/31/2023, PI, 550,000

2. Based on intestinal microbiota - regulatory T cell - PI3K/Akt/mTOR pathway to explore immune tolerance of mice heart transplantation induced by fecal bacteria transplantation combined with Chailing decoction in mice, The Natural Science Foundation of Shenzhen Science and Technology Innovation Commission, 01/01/2020 to 02/28/2023, PI, 300,000

3. Study on arsenic trioxide reducing regulatory T cells in the treatment of colon cancer, The Natural Science Foundation of Shenzhen University General Hospital, 06/01/2018 to 12/31/2020, 100,000, PI